PET technique promises better detection and response assessment for Non-Hodgkin's lymphoma

December 21, 2011, Society of Nuclear Medicine

Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method for imaging a form of Non-Hodgkin's disease called mantle cell lymphoma, a relatively rare and devastating blood cancer. The pilot study is published in the December issue of the Journal of Nuclear Medicine.

Lymphoma is the term used for an array of cancers that affect and the lymphatic system. These cancers are typically categorized as either Hodgkin's or non-Hodgkin's. Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma that accounts for approximately 6 percent, or roughly 3,000, of lymphoma cases in America, with prevalence in male populations over 60 years of age. MCL is caused by expression of B-cell lymphocytes within the mantle zone of lymph nodes. Normally these cells produce antibodies involved in the body's natural immune response, but in MCL these cells divide uncontrollably and don't terminate as healthy B-cells do.

The imaging agent being evaluated is called 3′-deoxy-3′-[F-18] fluorothymidine, or 18-F FLT. The combination of radionuclide and an analog of thymidine, a naturally occurring chemical compound that helps synchronize cell cycles, could provide a powerful biomarker for MCL.

"The encouraging results of this study should usher in new trials to investigate the role of FLT-PET for therapy response assessment and post-treatment monitoring," said one of the principal scientists, Ulrich Keller. "With further research, FLT-PET could be implemented to provide highly sensitive imaging for patients with MCL."

Researchers evaluated participants of the study using a variety of conventional imaging methods. One week before scheduled treatment with immunochemotherapy patients underwent both FLT-PET and FDG PET/CT, another method that targets the high glucose metabolism of . Five of these subjects had FLT-PET imaging performed again an average of about six days after the start of treatment to assess therapy response. Results showed all cancerous lesions found with more conventional imaging methods were very highly visible using FLT-PET. Correlation between areas of intense cancer proliferation and "high spots" of F-18 FLT on PET scans was performed using immunostaining, a technique that involves staining sections of tissues with antibodies in order to detect a particular biochemical process.

"MCL is still considered a non-curable disease, despite major advances in the clinical management of disease, underlining the need for reliable response assessment and post-treatment monitoring," added Keller. "The most widely used PET imaging agents have not yet proven to be beneficial for either one of them, which indicates FLT-PET's potential for MCL imaging."

Further research is expected to be conducted to confirm the efficacy of FLT-PET for initial detection and early response assessment of MCL.

Explore further: Combined imaging agents advance PET imaging of cancer

More information: "A pilot study to evaluate FLT-PET for initial and very early response imaging in MCL", Journal of Nuclear Medicine.

Related Stories

Combined imaging agents advance PET imaging of cancer

June 6, 2011
Research presented at SNM's 58th Annual Meeting is taking targeted molecular imaging to a new level by combining two commonly used imaging agents into one molecular imaging procedure. The combination of these agents creates ...

Novel imaging agent targets breast tumor development

June 6, 2011
Scientists presented new research at SNM's 58th Annual Meeting that has the potential to help physicians detect breast cancer by imaging the proliferation of blood vessels carrying oxygen and nutrients to breast tumors. Their ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.